RESOURCES

Our team partnered with an early-stage biotech on an A_2A receptor antagonist program initially targeting Parkinson’s disease.

Dose-response Relationships Across Clinically Relevant Human Targets

Assessing Fcγ receptor (FcγR) binding is an essential part of therapeutic antibody characterization, as these interactions influence a molecule’s effector function, safety profile, and mechanism of action.

Drug-induced Liver Injury (DILI) remains a major obstacle in drug development. Despite the use of various models, DILI continues to lead to drug attrition, post-market withdrawals, and safety warnings.

Clinical attrition of drug candidates is frequently driven by unforeseen safety liabilities, which are often associated with off-target pharmacological interactions.

The Adenosine A_2A Receptor (A_2AR) was selected as a representative GPCR to establish an integrated fragment‑based discovery workflow capable of screening fragments on the active receptor state.

We present integrated capabilities for SH2 domain-focused drug discovery, emphasizing STAT protein binding affinity and targeted protein degradation (TPD).

Obesity is a chronic, multifactorial disease projected to affect over 50% of the global population by 2035.

WEE1 is a key regulator of the G2/M cell cycle checkpoint, inhibiting CDK1 to allow DNA repair before mitosis.

Explore the mechanistic basis and translational implications of GPCR biased agonism. Examine via modern GPCR functional assays the (1) detection and quantification of signaling bias, (2) influence of bias signaling on the therapeutic profiles of existing and emerging drugs. and (3) use of quantitative pharmacological tools to enable systematic comparison of biased agonists.

Per- and polyfluoroalkyl substances (PFAS) are persistent environmental contaminants posing significant health risks, including endocrine disruption, hepatotoxicity, immuno-toxicity, and developmental effects.

Secondary pharmacology data plays a critical role in new drug applications by characterizing the selectivity profiles of clinical candidates and identifying off-target molecular interactions.